The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ConforMIS been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
ConforMIS is one of 841 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CFMS is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CFMS's full-year earnings has moved 28.90% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CFMS has moved about 50.78% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.14% on average. This means that ConforMIS is outperforming the sector as a whole this year.
Looking more specifically, CFMS belongs to the Medical - Instruments industry, which includes 90 individual stocks and currently sits at #88 in the Zacks Industry Rank. Stocks in this group have gained about 7.39% so far this year, so CFMS is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CFMS as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ConforMIS been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
ConforMIS is one of 841 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CFMS is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CFMS's full-year earnings has moved 28.90% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CFMS has moved about 50.78% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.14% on average. This means that ConforMIS is outperforming the sector as a whole this year.
Looking more specifically, CFMS belongs to the Medical - Instruments industry, which includes 90 individual stocks and currently sits at #88 in the Zacks Industry Rank. Stocks in this group have gained about 7.39% so far this year, so CFMS is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CFMS as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>